| |JULY 202219INDIAN PHARMACEUTICAL INDUSTRY & ITS GLOBAL IMPACTBy Dr R B Smarta, Managing Director, Interlink Marketing ConsultingA s of today, around 70 percent of critical Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs)are imported. The PLl scheme is meant for promotion of domestic manufacturing of critical KSMs, Drug intermediates and APIs in India. These incentives have been provided to 41 eligible products which covers 53 APIs for six years. The rates vary as per the technology. PLI 2.0 was launched with an objective of increasing investment in production, help product diversification and create global champions out of India who have the potential to grow with cutting edge technology. I believe both schemes are excellent opportunities for Indian Pharma. I am sure the industry will take advantage of these schemesto not only ease the burden of imports and become Atmanirbhar in APIs, but also establish the country's credentials as an innovator on global pharmaceutical stage. INDIA'S IMPRESSION IN GLOBAL STAGEVaccines from India have been well received the by world. While the Indian Govt is requesting for support from other countries to provide raw materials, it has also obliged them by sending part of its production to those countries which are supporting it in creating vaccines.In this way, the India Pharma industry is driving a narrative of quality and affordable prices with Indian vaccines. Globally it will substantiate an image of safety, quality and affordability.As it is Pharmaexil is working for so many years in creating exports to Global markets, providing them sustainable and quality resource pharma products.In my opinion, it will substantiate and increase the India's image in the world.UNIVERSAL HEALTHCARE ININDIA -A REALITY?Universal healthcare denotes a broad term wherein the Government ensures access to quality healthcare services for all its citizens while ensuring the use of these services does not result in financial hardships to those who avail of it. From an India perspective, our healthcare system is highly fragmented at this moment. While innovation and digitization can play a significant role in driving access, providing Government support or insurance coverage may Dr R B Smarta, Managing DirectorINDUSTRY INSIGHTS
< Page 9 | Page 11 >